Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Cyclerion Therapeutics, Inc is a biotechnology business based in the US. Cyclerion Therapeutics shares (CYCN) are listed on the NASDAQ and all prices are listed in US Dollars. Cyclerion Therapeutics employs 94 staff and has a trailing 12-month revenue of around USD$3.6 million.
|Latest market close||USD$3.22|
|52-week range||USD$2.0769 - USD$8.96|
|50-day moving average||USD$3.0202|
|200-day moving average||USD$4.7036|
|Wall St. target price||USD$4|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.736|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-08)||-1.23%|
|1 month (2020-12-16)||2.22%|
|3 months (2020-10-15)||8.42%|
|6 months (2020-07-15)||-35.21%|
|1 year (2020-01-15)||-4.73%|
|2 years (2019-01-12)||N/A|
|3 years (2018-01-12)||N/A|
|5 years (2016-01-12)||N/A|
|Revenue TTM||USD$3.6 million|
|Gross profit TTM||USD$4.5 million|
|Return on assets TTM||-33.46%|
|Return on equity TTM||-87%|
|Market capitalisation||USD$106 million|
TTM: trailing 12 months
There are currently 592,674 Cyclerion Therapeutics shares held short by investors – that's known as Cyclerion Therapeutics's "short interest". This figure is 3.6% down from 614,703 last month.
There are a few different ways that this level of interest in shorting Cyclerion Therapeutics shares can be evaluated.
Cyclerion Therapeutics's "short interest ratio" (SIR) is the quantity of Cyclerion Therapeutics shares currently shorted divided by the average quantity of Cyclerion Therapeutics shares traded daily (recently around 392499.33774834). Cyclerion Therapeutics's SIR currently stands at 1.51. In other words for every 100,000 Cyclerion Therapeutics shares traded daily on the market, roughly 1510 shares are currently held short.
However Cyclerion Therapeutics's short interest can also be evaluated against the total number of Cyclerion Therapeutics shares, or, against the total number of tradable Cyclerion Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cyclerion Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cyclerion Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0191% of the tradable shares (for every 100,000 tradable Cyclerion Therapeutics shares, roughly 19 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cyclerion Therapeutics.
Find out more about how you can short Cyclerion Therapeutics stock.
We're not expecting Cyclerion Therapeutics to pay a dividend over the next 12 months.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.